Calcium Absorption Randomized Trial: What the Evidence Says

Quick Answer

Calcium Absorption Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Causes and contributing factors include inadequate intake, malabsorption, chronic blood loss, and increased demands related to growth, menstruation, or pregnancy. [García-Erce José Antonio (2026); evidence level 3]
• During pregnancy, iron requirements triple to support fetal growth, placental function, and maternal red cell expansion, increasing the risk of maternal morbidity, and peri- and postpartum consequences. [García-Erce José Antonio (2026); evidence level 3]
• In addition, hyperphosphatemia is associated with secondary hyperparathyroidism, which may further exacerbate hyperphosphatemia through the increased phosphate release from the bone. [Parpia Arti Sharma (2026); evidence level 3]
• Hyperphosphatemia has classically been associated with uremic pruritus but this relationship has recently been questioned. [Parpia Arti Sharma (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For calcium absorption randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• García-Erce José Antonio (2026). Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice. DOI: 10.3390/jcm15103691. PMCID: PMC13208006. PMID: 42194653. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13208006/
• Parpia Arti Sharma (2026). Phosphate—latest news and ongoing trials. DOI: 10.1093/ckj/sfag108. PMCID: PMC13270310. PMID: 42311904. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13270310/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.